KLK3 and posterior cortical atrophy: Recent prostate specific antigen (PSA) testing guidelines have implications for long-term surveillance, outcomes, and cost of PCa care.[2] With a median age at diagnosis of 68 years, many patients, especially those with localized tumor, die of other illnesses.[1–3] Although PCa-related mortality has been declining since 1994, the aging baby boomers will increase the future absolute burden of PCa.[4]